About Hepion Pharmaceuticals

About company

Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). Its drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Its former name is ContraVir Pharmaceuticals. It was founded in 2013 and is based in Edison, New Jersey.